Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

Karin Fjordén, Sara Ekberg, Nevzeta Kuric, Karin E Smedby, Ingemar Lagerlöf, Thomas S Larsen, Judit M Jørgensen, Peter de Nully Brown, Mats Jerkeman

5 Citations (Scopus)
Original languageEnglish
JournalBritish Journal of Haematology
Volume196
Issue number2
Pages (from-to)437-440
Number of pages4
ISSN0007-1048
DOIs
Publication statusPublished - Jan 2022

Keywords

  • Idelalisib
  • relapsed/refractory DLBCL
  • transformed lymphoma

Cite this